CapsoVision to Pitch AI-Powered GI Diagnostics at ROTH Conference

SARATOGA, CA – March 09, 2026 – CapsoVision, Inc. (NASDAQ: CV), a medical technology company developing advanced capsule endoscopy solutions, announced today that its top executives will participate in the 38th Annual ROTH Conference later this month. The event provides a crucial platform for the company to engage with the investment community as it seeks to solidify its position in the competitive gastrointestinal diagnostics market.

President and CEO Johnny Wang, Senior Vice President of Finance David Garcia, and Senior Vice President of Global Sales Doug Atkinson are scheduled to host a fireside chat on March 23 in Dana Point, California. The leadership team will also conduct one-on-one meetings, offering investors a direct line to the company's strategic vision for its AI-enabled imaging technologies.

A High-Stakes Pitch for a Growth-Stage Company

For CapsoVision, the ROTH Conference is more than a routine investor relations event; it is a strategic opportunity to build momentum following its Initial Public Offering in July 2025, which raised $27.5 million. The company, now in its commercial stage, arrives with a mixed but promising financial profile that will be under intense scrutiny from analysts and potential backers.

Recent financial reports show encouraging top-line growth, with revenue for the second quarter of 2025 reaching $3.3 million, a 17% increase over the prior year, driven by a 75% expansion in new accounts. However, this growth comes at a cost. The company reported a net loss of over $22 million in the last twelve months and a significant operating cash outflow. This dynamic is common for growth-stage medtech firms, which invest heavily in research, development, and market penetration before achieving profitability.

Investors at the conference will be looking for a clear narrative from Wang and Garcia on the company's path to profitability. Analyst sentiment currently reflects cautious optimism, with a consensus “Moderate Buy” rating and an average 12-month price target of $6.00, suggesting potential upside. However, a recent uptick in short interest indicates that some market participants remain skeptical. CapsoVision's leadership will need to effectively communicate how its technological advantages and market strategy will translate into sustainable financial returns.

Revolutionizing Diagnostics from the Inside Out

At the core of CapsoVision's investor pitch is its flagship product, CapsoCam Plus®, a capsule endoscope designed for visualizing the small bowel. Unlike competing systems, CapsoCam Plus® features a wire-free design with 360-degree panoramic imaging. The device stores video data internally, which clinicians can later access through a secure cloud platform or direct download. This eliminates the need for patients to wear cumbersome external data recorders and wires for hours, a significant improvement in patient comfort and experience.

To date, the CapsoCam Plus® has been used in over 143,000 procedures, demonstrating growing clinical adoption. The company's primary competitor, Medtronic, which pioneered the market with its PillCam™ platform, offers robust technology but relies on the traditional data recorder model. CapsoVision is betting that its streamlined, patient-centric workflow will be a key differentiator in capturing market share.

The company is also looking to expand its reach within the GI tract with its pipeline product, CapsoCam Colon™. This next-generation capsule aims to provide a non-invasive method for colon imaging and polyp detection, a massive market currently dominated by traditional colonoscopy. Success in this area would represent a monumental step forward for both the company and for patient care.

The AI Edge in a Crowded Field

A pivotal element of CapsoVision's future growth strategy is the integration of artificial intelligence. Reviewing the tens of thousands of images captured during a single capsule endoscopy procedure can be a laborious and time-consuming task for gastroenterologists, often taking between 30 and 90 minutes. This creates a bottleneck in clinical workflow and introduces the potential for human error, where subtle abnormalities might be missed.

AI offers a powerful solution to this challenge. Advanced algorithms, trained on vast datasets of endoscopic images, can analyze videos in a fraction of the time while flagging potential lesions with remarkable accuracy. Studies have shown that AI-assisted reading can reduce review times to under ten minutes and achieve sensitivity and specificity rates exceeding 90% for detecting issues like polyps and inflammation.

CapsoVision is actively moving to capitalize on this trend. In December 2025, the company announced it had submitted a 510(k) premarket notification to the FDA for an AI-assisted reading module for its CapsoCam Plus® system. This technology is designed to help physicians identify abnormalities more efficiently and accurately. By embedding AI into its platform, CapsoVision aims to not only enhance its current offerings but also position itself at the forefront of a major technological shift in digestive health diagnostics.

Leadership Team on Display

The decision to have its CEO, head of finance, and head of global sales lead the engagement at the ROTH Conference underscores the company's commitment to transparency and strategic communication. The team brings a formidable combination of technical, financial, and commercial expertise.

CEO Johnny Wang, a co-founder of the company, has a deep engineering background that has guided CapsoVision's product development from its inception. David Garcia, who joined as SVP of Finance in late 2025, brings critical experience in financial planning and capital markets, having played a key role in the IPO of a previous company. Doug Atkinson, a 30-year veteran of the medical device industry with leadership experience at giants like Medtronic and Stryker, provides the commercial acumen needed to execute the company's global sales strategy.

This well-rounded team is uniquely equipped to address the multifaceted questions of the investment community, from the technical specifications of their capsules to the financial modeling of their growth trajectory. Their direct participation signals to investors that the company's leadership is accessible, confident in its strategy, and prepared to build the long-term relationships necessary for success in the public market. As CapsoVision takes the stage, it will be their collective ability to articulate a compelling and credible vision for the future of GI diagnostics that will ultimately determine their reception.